Association between chronic hepatitis B virus infection and risk of osteoporosis: A nationwide population-based study

Medicine (United States)

Volumn 94, Issue 50, 2015, Pages

  Chen, Chien Hua ^a,b,c   Lin, Cheng Li ^d,e   Kao, Chia Hung ^f,g  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d China Medical University Hospital   (China)

^e Department of Human Nutrition School of Medicine College of Medical Veterinary and Life Sciences   (United Kingdom)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROTON PUMP INHIBITOR; STEROID; WARFARIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CHRONIC HEPATITIS B; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPOROSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; THYROID DISEASE; COHORT ANALYSIS; COMPLICATION; FACTUAL DATABASE; HEALTH INSURANCE; HEPATITIS B; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TAIWAN; VIROLOGY;

ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TAIWAN;

EID: 84952670650     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002276     Document Type: Article

References (39)

1. Consensus Development Conference: Prophylaxis and treatment of osteoporosis. Osteoporosis Int. 1991;1:114-117.
2. Kinsella K, Wan H. International Population Reports. P95/09-1. An Aging World:2008. Washington, DC: US Census Bureau, US Government Printing Office; 2009.
3. Cooper C, Cole ZA, Holroyd CR, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277-1288.
4. Suman VB, Khalid P, Pratik KC. Risk factors associated with osteoporosis. Int J Health Sci Res. 2013;3:85-91.
5. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:117-1141.
6. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-589.
7. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158-S168.
8. Chen YL, Yang JY, Lin SF, et al. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2005;63:354-363.
9. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843-1847.
10. Gill US, Zissimopoulos A, Al-Shamma S, et al. Assessment of bone mineral density in Tenofovir-treated patients with chronic hepatitis B: can the fracture assessment tool identify those at greatest risk? JID. 2015;211:347-382.
11. Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 2002;277:2695-2701.
12. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocinol Metab. 2004;89:4325-4330.
13. Database NHIR. Taiwan, http://nhird.nhri.org.tw/en/index.html. (cited in 2015/11/26).
14. Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos. 2012;7:3-20.
15. Byrne DD, Newcomb CW, Carbonari DM, et al. Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol. 2014;61:210-218.
16. Chien YC, Jan CF, Kuo HS, et al. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126-135.
17. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol. 1983;117:213-222.
18. Su WJ, Liu CC, Liu DP, et al. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. JID. 2012;205:757-762.
19. Locarnini S, Hatzakis A, Chen DS, et al. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62:S76-S86.
20. Jinjuvadia R, Liangpunsakul S. Association between metabolic syndrome and its individual components with viral hepatitis B. Am J Med Sci. 2014;347:23-27.
21. Targher G, Bertolini L, Padovani R, et al. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126-1132.
22. Jan CF, Chen CJ, Chiu YH, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung community-based integrated screening study no. 10). Int J Obes Relat Metab Disord. 2006;30:794-799.
23. Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SERBP1 and PPARgamma. Gastroenterology. 2007;132:1955-1967.
24. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26:628-638.
25. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med. 1997;102:35S-39S.
26. Riggs BL, Melton LT III, Evans TG, et al. Involutional osteoporosis. In. Oxford Textbook of Geriatric Medicine. London: Oxford University Press,; 1992.
27. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 2003;18:1795-1802.
28. Derakhshanfar A, Kheirandish R, Alidadi S, et al. Study of long effects of administration of aspirin (acetylsalicyclic acid) on bone in broiler chickens. Comp Clin Pathol. 2013;22:1201-1204.
29. De Luna-Bertos E, Ramos-Torrecillas J, Manzano-Moreno FJ, et al. Effects on growth of human osteoblast-like cells of three nonsteroidal anti-inflammatory drugs metamizole, dexketoprofen, and ketorolac. Biol Res Nurs. 2015;17:62-67.
30. Lopez-Larramona G, Lucendo AJ, Gonzalez-Castillo S, et al. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Gastroenterol. 2011;3:300-307.
31. Rouillard S, Lane NE. Hepatic osteodystropthy. Hepatology. 2001;33:301-307.
32. Pignata S, Daniele B, Galati MG, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1997;9:283-286.
33. Van Leeuwen JP, Van Driel M, Van Den Bemd GJ, et al. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene expr. 2001;11:199-226.
34. Lindor KD, Janes CH, Crippen JS, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid acid make a difference? Hepatology. 1995;21:389-392.
35. Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol. 2014;20:9427-9438.
36. Krieger NS, Frick KK, Bushinsky DA. Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens. 2013;14:311-317.
37. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995;95:2581-2586.
38. Chen SJ, Lin CS, Lin CL, et al. Osteoporosis is associated with high risk for coronary artery disease: a population-based cohort study. Medicine. 2015;94:e1146.
39. Chang KH, Chang MY, Muo CH, et al. Exposure to air pollution increases the risk of osteoporosis: a nationwide longitudinal study. Medicine. 2015;94:e733.